Flush communication channels: Effective implementation and verification

Flush communication channels, or F-channels, generalize more conventional asynchronous communication paradigms. A distributed system which uses an F-channel allows a programmer to define the delivery order of each message in relation to other messages transmitted on the channel. Unreliable datagrams and FIFO (first-in-first-out) communication channels have strictly defined delivery semantics. No restrictions are allowed on message delivery order with unreliable datagrams--message delivery is completely unordered. FIFO channels, on the other hand, insist messages are delivered in the order of their transmission. Flush channels can provide either of these delivery order semantics; in addition, F-channels allow the user to define the delivery of a message to be after the delivery of all messages previously transmitted or before the delivery of all messages subsequently transmitted or both. A system which communicates with a flush channel has a message delivery order that is a partial order.;Dynamically specifying a partial message delivery order complicates many aspects of how we implement and reason about the communication channel. From the system\u27s perspective, we develop a feasible implementation protocol and prove its correctness. The protocol effectively handles the partially ordered message delivery. From the user\u27s perspective, we derive an axiomatic verification methodology for flush applications. The added flexibility of defining the delivery order dynamically slightly increases the complexity for the application programmer. Our verification work helps the user effectively deal with the partially ordered message delivery in flush communication

The Sticking Heartbeat Aperture Resynchronization Protocol

International audienceAs wireless sensor networks become more ubiquitous in the world, the need for lightweight, resilient time synchronization protocols is apparent. Wireless nodes’ internal clocks are subject to drift over time due to manufacturing imperfections and environmental changes. While various protocols have been introduced that attempt to correct for this drift, they each have their own peculiarities and issues. This paper presents a new protocol, the Sticking Heartbeat Aperture Resynchronization Protocol (SHARP), that reduces synchronization error and resolves shortcomings of existing protocols. We have implemented and compared SHARP to two existing (and noteworthy) time synchronization protocols, Reference Broadcast Synchronization (RBS) and Simple Synchronization Protocol (SISP), on Atmel ATMega328p based microcontroller platforms with IEEE 802.15.4 Xbee radio modules. We show that SHARP exhibits a higher level of synchronization than SISP (which in turn exhibited much better performance than RBS), while requiring significantly fewer messages

10 Years of Networking Networking Women

International audienceNetworking Networking Women (N2Women) celebrated its 10-year anniversary at the fifth N2Women Workshop co-located with MobiCom 2016. Founded in 2006 by Tracy Camp and Wendi Heinzelman, N2Women is a discipline-specific community for researchers in the communications and networking field. The main goal of N2Women is to foster connections among the underrepresented women in computer networking and related research fields. N2Women allows women to connect with other women who share the same research interests, who attend the same conferences, who face the same career hurdles, and who share common career objectives

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo